Leyden Labs Secures €30 Million to Boost Nasal Spray Development
Leiden, Thursday, 2 October 2025.
Leyden Labs, a Dutch biotech company, has raised €30 million to advance its PanFlu nasal spray aimed at combating respiratory viruses, reflecting strong European investor confidence.
A Significant Boost for Respiratory Health Innovation
Leyden Labs has recently secured a €30 million investment from the European Innovation Council (EIC) Fund and Invest-NL, marking a significant milestone in the advancement of their PanFlu nasal spray. This nasal spray is designed to provide protection against a variety of respiratory viruses, including influenza, by stopping infections at their point of entry—the nasal cavity. Leyden Labs, based in Leiden, Netherlands, is leading this innovative approach under the guidance of its co-founder and CEO, Koenraad Wiedhaup [1][2][3][4].
The Science Behind PanFlu
The PanFlu nasal spray represents a novel approach in the field of biopharmaceuticals. Unlike traditional vaccines, this nasal spray uses antibody-based technology to create a barrier in the nasal passages, effectively preventing the entry of viruses. This method offers rapid protection, which is particularly crucial during the early stages of infection exposure. The technology leverages the body’s mucosal immune system, which is the first line of defense against airborne pathogens, providing a proactive solution to respiratory viral threats [1][4][5].
Impact and Future Prospects
The €30 million funding is not just a financial boost for Leyden Labs but also serves as an endorsement of their innovative efforts in the realm of respiratory health. European investors, particularly the EIC Fund and Invest-NL, have shown strong confidence in the potential of the PanFlu spray to significantly impact public health. This investment will facilitate further development and commercialization, potentially leading to a new standard in preventing respiratory infections [1][2][4].
Leadership and Vision
Under the leadership of Koenraad Wiedhaup, Leyden Labs continues to forge ahead with a clear mission: to enhance public health through innovative, non-vaccine solutions. The company’s focus on developing products like PanFlu underscores its commitment to addressing global health challenges with cutting-edge technology. The support from notable figures like Paméla Grondin and other key stakeholders within Leyden Labs further strengthens the company’s resolve to make a meaningful impact in the biopharmaceutical industry [1][2][3][4].